Home Health Care Stock in the Spotlight: Vericel Corp (NASDAQ:VCEL)

Stock in the Spotlight: Vericel Corp (NASDAQ:VCEL)


Intraday Info: Vericel Corp (NASDAQ:VCEL) locked on 10/01/2017 at $2.85. It has average volume 3.19 million whilst it totals volume 811,126. The company has EPS -1.12 and according to analysts next quarter EPS and next year estimate EPS will -0.18 and -0.48 respectively. Profit Margin of VCEL -48.10% and it total income 92.45 million.

Ownership Summary: Vericel Corp has total institutional ownership 24.40% while its total outstanding shares 32 millions that’s value of holdings $23 million.

Active Positions: In the latest year, VCEL 12 holders have raised its positions while it contains total 124,185 shares. And the strength of reduced positions holders and held positions holders are 27 and 15 respectively.

New and Sold Out Positions: In VCEL force of new positions holders 2 and it has total shares 42,707. And force of sold out positions holders 9 and it has 2,586,024 shares.

Comparison with Other Company: The Market Value of VCEL is $68,705 below from Seattle Genetics, Inc. market value which is $8M. Current Last Sale of VCEL is $2.85 below from SGEn current last sale which is $5.01.

Vericel Corp researches, develops, manufactures, markets, and sells affected person-precise multiplied cell remedies for use in the treatment of sufferers with severe sicknesses and situations. It markets  autologous mobile remedy products, counting Carticel, an autologous chondrocyte implant for the treatment of cartilage defects inside the knee; and Epicel, a permanent pores and skin alternative for the remedy of sufferers with deep-dermal or complete-thickness burns comprising extra than or same to 30 percent of overall body surface region within the america. The company is likewise growing MACI, a third-technology autologous chondrocyte implant for the remedy of cartilage defects within the knee; and ixmyelocel-T, that’s in section IIb scientific trial, a affected person-unique multicellular therapy for the remedy of advanced heart failure because of ischemic dilated cardiomyopathy. The company became previously known as Aastrom Biosciences, Inc. Vericel agency turned into based in 1989 and is situated in Cambridge, Massachusetts.